Analysts Offer Predictions for Novartis FY2024 Earnings

Novartis AG (NYSE:NVS) – Investment analysts at Zacks Research increased their FY2024 EPS estimates for shares of Novartis in a report issued on Tuesday, November 12th. Zacks Research analyst E. Bagri now anticipates that the company will earn $7.59 per share for the year, up from their previous forecast of $7.51. The consensus estimate for Novartis’ current full-year earnings is $7.63 per share. Zacks Research also issued estimates for Novartis’ Q1 2025 earnings at $1.94 EPS, Q2 2025 earnings at $2.08 EPS, Q1 2026 earnings at $2.06 EPS and FY2026 earnings at $8.89 EPS.

Novartis (NYSE:NVS) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $2.06 EPS for the quarter, beating the consensus estimate of $1.94 by $0.12. Novartis had a net margin of 35.96% and a return on equity of 34.80%. The firm had revenue of $12.82 billion for the quarter, compared to analyst estimates of $12.62 billion. During the same quarter last year, the firm posted $1.74 earnings per share.

NVS has been the topic of a number of other research reports. Bank of America cut Novartis from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $135.00 to $130.00 in a research note on Wednesday, September 11th. BMO Capital Markets upped their price target on Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a report on Wednesday, October 30th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Novartis in a research report on Friday, July 19th. Jefferies Financial Group downgraded shares of Novartis from a “buy” rating to a “hold” rating in a research note on Tuesday, September 3rd. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and set a $121.00 price target (up previously from $119.00) on shares of Novartis in a research note on Thursday, September 5th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $121.50.

Novartis Stock Performance

NYSE:NVS opened at $103.06 on Thursday. The firm’s fifty day simple moving average is $113.41 and its 200 day simple moving average is $109.79. The company has a current ratio of 1.11, a quick ratio of 0.90 and a debt-to-equity ratio of 0.55. Novartis has a twelve month low of $92.35 and a twelve month high of $120.92. The firm has a market capitalization of $210.65 billion, a price-to-earnings ratio of 11.93, a PEG ratio of 1.50 and a beta of 0.58.

Hedge Funds Weigh In On Novartis

Several large investors have recently modified their holdings of NVS. Dimensional Fund Advisors LP grew its position in shares of Novartis by 23.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 7,407,692 shares of the company’s stock worth $788,626,000 after acquiring an additional 1,389,610 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Novartis by 191.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,904,664 shares of the company’s stock valued at $202,771,000 after purchasing an additional 1,250,318 shares during the period. Magnetar Financial LLC grew its position in shares of Novartis by 53.7% during the first quarter. Magnetar Financial LLC now owns 1,906,046 shares of the company’s stock worth $184,372,000 after acquiring an additional 666,104 shares during the last quarter. Canada Pension Plan Investment Board acquired a new position in Novartis during the 2nd quarter valued at about $64,610,000. Finally, Bank of Montreal Can grew its position in Novartis by 343.5% in the 2nd quarter. Bank of Montreal Can now owns 657,903 shares of the company’s stock worth $70,652,000 after purchasing an additional 509,567 shares during the last quarter. Institutional investors own 13.12% of the company’s stock.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.